Dermot McGovern completed his GI fellowship and obtained a PhD in complex disease genetics at the University of Oxford before moving to Cedars-Sinai, Los Angeles almost 10 years ago. Dr McGovern’s clinical practice is in a tertiary referral center for complex IBD. Dr McGovern serves on the National Scientific Advisory Committee for the Crohn’s and Colitis Foundation of America as well as the steering committees of the National and International IBD Genetics Consortia. He also chairs the CCFA local advisory medical committee. His group is funded by the NIH to study the effect of genetics on the susceptibility to and natural history of IBD in diverse populations. Dr McGovern’s group analyze multi’-omic’ datasets to identify potential therapeutic targets of IBD that ‘feed’ the Drug Development Unit he co-directs. He is a member of the American Society for Clinical Investigation and also the International Organization for the Study of IBD (IOIBD). Dr McGovern has recently been appointed the Director of the Cedars-Sinai Precision Medicine Initiative.